Single-Cell Sequencing Reveals the Overall Changes in Tumor Microenvironment Mediated by CD39i

Here we identified the ecto-enzyme, CD39 (encoded by ENTPD1), as a potential therapeutic target for BC via single-cell transcriptome analysis of BC and para-cancer tissues. In a subcutaneous model, inhibition of CD39 (CD39i) is able to limit the growth of BC and improve overall survival of tumor-bearing mice. Via single-cell sequencing of tumor infiltrated immune cells, we found that CD39i with POM-1 increased the intratumor NK cells, conventional type 1 dendritic cells (cDC1) and CD8+ T cells, along with decreased Treg abundance. The anti-tumor effect and reprogram of tumor microenvironment are blockade in a cDC1-deficient Batf3-/- model. Overall design: Comparing changes in TME caused by CD39i.